Latest Sales Performance News

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Cedar Woods Properties has raised its FY26 net profit guidance to at least 20% growth, driven by strong sales and faster project delivery, setting the stage for record earnings and higher dividends.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

AdNeo Limited’s subsidiary Learnt has landed a significant 12-month contract with Hisense Australia to deliver a comprehensive corporate learning and loyalty platform, marking a strategic expansion in the enterprise learning market.

The Agency Group Australia has set a new record by surpassing $1 billion in residential property sales in November 2025, driven by strong market activity and agent productivity across multiple states.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

Harvey Norman Holdings reports a robust 9.1% increase in aggregated sales revenue across key international markets, supported by currency appreciation and selective store openings.

Finbar Group has completed settlement on a prime South Perth development site valued at approximately $187 million, advancing its substantial $1.2 billion project pipeline with a market launch planned for 2026.

Oceania Healthcare has posted a strong half-year turnaround with improved sales, cost savings, and reduced gearing, setting the stage for renewed growth and operational strength.

Finbar Group Limited highlights strong sales momentum in 2025, underpinned by a $1.2 billion development pipeline and a buoyant Western Australian apartment market driven by migration and undersupply.

Briscoe Group reports a slight sales decline in Q3 2025 but stabilizes gross profit margins and advances key strategic projects, positioning itself cautiously for the critical fourth quarter.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.